News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Media Contact:
Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc
ARMONK N.Y. and TOKYO, March 26, 2014 – IBM and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced they are teaming to deliver a novel solution intended to improve care coordination in the mental health community. Many challenges face mental healthcare delivery networks worldwide. Currently, almost 10 percent of patients discharged from a state psychiatric hospital in the U.S. are
TOKYO, JAPAN, August 5, 2013Otsuka Pharmaceutical Co., Ltd. announced today the U.S. Food and Drug Administration’s (FDA's) Cardiovascular and Renal Drugs Advisory Committee voted 9 to 6 not to approve tolvaptan for the treatment of ADPKD. The FDA is not bound by the Committee’s guidance but takes its advice into consideration. “While we are disappointed in the Committee’s
PRINCETON, N.J., June 20, 2013 (BUSINESS WIRE) Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka America Pharmaceutical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Sprycel (dasatinib) product labeling. The labeling now includes three-year efficacy and safety data in patients with newly diagnosed Philadelphia chromosome-positive (Ph+)
ROCKVILLE, M.D. AND PRINCETON, N.J., June 4, 2013 Otsuka America Pharmaceutical, Inc. (OAPI) announced today that BreathTek® UBT for H. pylori Kit (BreathTek UBT Kit) may be administered to patients who are taking proton-pump inhibitors (PPIs). Patients who took PPIs within the last 2 weeks can still be tested according to the updated BreathTek UBT Kit labeling, but the test result needs to